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A B S T R A C T
Background: The National Institute for Health and Care Excellence (NICE) developed a guideline on drug misuse
prevention in vulnerable populations. Part of the guideline development process involved evaluating cost-effec-
tiveness and determining which interventions represented good value for money.
Methods: Economic models were developed for seven interventions which aimed to prevent drug use in vulner-
able populations. The models compared the costs (to the health and crime sectors) and health benefits (in qual-
ity-adjusted life years (QALYs)) of each intervention and its comparator. Sensitivity analysis explored the uncer-
tainty associated with the cost of each intervention and duration of its effect.
Results: The reduction in drug use for each intervention partly offset the costs of the intervention, and improved
health outcomes (QALYs). However, with high intervention costs and low QALY gains, none of the interventions
were estimated to be cost-effective in the base case. Sensitivity analysis found that some of the interventions
could be cost-effective if they could be delivered at a lower cost, or if the effect could be sustained for more than
two years.
Conclusions: For drug misuse prevention to be prioritised by funders, the consequences of drug misuse need to be
understood, and interventions need to be shown to be effective and cost-effective. Quantifying the wider harms
of drug misuse and wider benefits of prevention interventions poses challenges in evaluating the cost-effective-
ness of drug misuse prevention interventions. A greater understanding of the consequences of drug misuse and
causal factors could facilitate development of cost-effective interventions to prevent drug misuse.
Introduction
In 2015, the Department of Health in England asked the National In-
stitute for Health and Care Excellence (NICE) to develop guidance on
drug misuse prevention (National Institute for Health & Care Excellence,
2017). The guideline scope focussed on interventions targeted at pop-
ulations who were already using drugs occasionally, or were consid-
ered at most risk of starting to use drugs. The scope considered groups
including (but not limited to) those with co-occurring men
tal health problems, those not in education, and children and young
people whose parents used drugs. The guideline focussed on interven-
tions that aimed to prevent or delay drug use and excluded interven-
tions related to the supply of drugs, treatment of drug misuse or depen-
dence and interventions to promote safer injecting (National Institute
for Health & Care Excellence, 2015).
NICE follows a defined process in developing guidelines that consid-
ers evidence for the effectiveness and cost-effectiveness of interventions
when making recommendations (National Institute for Health & Care
Excellence, 2016). In considering cost-effectiveness evidence, NICE’s
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preference is usually to conduct cost-utility analysis, using quality-ad-
justed life years (QALYs) as the outcome metric. QALYs combine qual-
ity of life with length of life, and therefore allow comparison of out-
comes across different health areas. An incremental cost-effectiveness
ratio (ICER) can be calculated by dividing the difference in costs of
an intervention and its comparator by the difference in QALYs. Judg-
ing the size of ICERs assists decision makers in determining whether
an intervention represents good value for money. (It should be noted
that cost-effectiveness is not the sole factor considered in NICE’s deci-
sion making, and that other elements such as the fair distribution of re-
sources should also be considered (National Institute for Health & Care
Excellence, 2008a)).
A systematic review of the literature did not identify any articles
that reported relevant cost-effectiveness evidence (Bates et al., 2016).
Three reports summarising findings from a US-based cost-benefit model
for interventions targeting relevant populations were identified from ad-
ditional sources, but these were considered to have limited applicabil-
ity to the UK setting. Given the absence of relevant cost-utility analysis
from the literature, the development of new economic models was con-
sidered important in understanding which interventions aimed at drug
misuse prevention represent good value for money. The economic mod-
els considered behavioural interventions identified in a systematic re-
view of the literature. None of the interventions considered in the eco-
nomic models were considered cost-effective using NICE’s standard ap-
proach.
This article aims to explore why these interventions were not cost-ef-
fective and how future economic evaluations should consider interven-
tions to prevent drug misuse. We do this by:
• providing an overview of the modelling approach and inputs and re-
porting the results of the analysis,
• providing sensitivity analysis to understand which parameters would
need to change for interventions to be cost-effective, and
• discussing the challenges of economic evaluation of drug misuse pre-
vention.
We draw comparison with alcohol and smoking, and refer to estab-
lished challenges in economic evaluation in public health. We discuss
the limitations of our analysis and suggest alternative approaches which
could be used in future analyses, and areas in which further research
would be particularly valuable.
Material and methods
General modelling approach
Economic modelling compares the costs and consequences of two al-
ternative courses of action. Models combine data from multiple sources
to estimate the total costs and benefits that would occur if each of
the two courses of action were implemented. Decision tree models
use ‘branches’ to represent the different pathways patients can fol-
low or events that can happen, and multiply the probabilities of these
events by the costs and consequences of the events (Brennan, Chick, &
Davies, 2006; Briggs, Claxton, & Sculpher, 2006; Drummond, Sculpher,
Torrance, O’Brien, & Stoddart, 2015; Morris, Devlin, & Parkin, 2007).
Decision trees are commonly used in evaluating the cost-effectiveness
of health interventions for drug or alcohol problems (Hoang et al.,
2016). We developed decision tree models to compare the costs and
QALYs associated with the change in drug use for each intervention
and its comparator in the study. We performed literature searches to
identify the events, costs and consequences which would be included
in the models. These required numerical data comparing outcomes be-
tween drug use and non-drug use such as relative risks or odds ratios.
Outcomes for which quantifiable effects could not be identified were
excluded from the models. Included events were discussed and agreed
with an advisory committee.
We adopted a partial public sector perspective, including costs to
healthcare and criminal justice sectors. We did not include costs relat-
ing to employment, education or out-of-pocket expenses incurred by
individuals. We considered health effects to the individuals at risk of
drug misuse, using QALY losses to capture the impact of both reduc-
tions in quality-of-life, and of premature death. The costs and oppor-
tunity for QALY gains for each intervention were specific to the drug
in question, as the potential consequences of cannabis, ecstasy and co-
caine usage differ and no single source was identified which reported
data for all drugs. Costs and QALYs were discounted at 3.5% per annum
(National Institute for Health & Care Excellence, 2016). All costs were
expressed in 2015 prices (GBP). The modelled time horizon (time period
over which events, costs and consequences are considered) depended
upon the duration of the study and evidence base for drug-related con-
sequences, and was varied in scenario analyses. Details of all the models
and inputs are available elsewhere (Collins et al., 2016).
Interventions
Interventions identified in a systematic literature review of the ef-
fectiveness of targeted prevention programmes (Novakovic et al., 2016)
were included in the models if they reduced drug misuse, the source
study included a comparator group, and the baseline characteristics of
the population in the study were defined. A total of seven interventions
met these criteria. These were:
1. Focus on Families: a multicomponent intervention with families of
substance abusers (Catalano, Gainey, Fleming, Haggerty, & Johnson,
1999).
2. A web-based personalised feedback intervention based on brief moti-
vational interviewing techniques, for college student cannabis users
(Lee, Neighbors, Kilmer, & Larimer, 2010).
3. Familias Unidas: a group based multi-parent intervention for families
of delinquent youth (Prado et al., 2012).
4. A single brief motivational interviewing session for regular ecstasy
users (Martin & Copeland, 2010).
5. A brief motivational interviewing intervention to reduce both risky
sex and drug use in young gay and bisexual men (Parsons,
Lelutiu-Weinberger, Botsko, & Golub, 2014).
6. A motivational interviewing intervention to reduce club drug and
HIV risk behaviours use among men who have sex with men
(Morgenstern et al., 2009).
7. STRIVE (SupporT to Reunite, Involve and Value Each other): A fam-
ily-based intervention to reduce substance use among newly home-
less youth (Milburn et al., 2012).
The effectiveness of the interventions was derived from the effec-
tiveness studies identified in the systematic review (Novakovic et al.,
2016). Population, intervention, comparator and effectiveness data are
presented in Table 1.
None of the studies provided UK costs for the interventions, so we
estimated intervention costs by converting costs from other currencies
to GBP, or by applying UK unit costs to reported resource use. UK prac-
tice may differ from the source studies, and there may be local varia-
tion in the implementation of the interventions, so the intervention costs
were varied in sensitivity analysis. Estimates including lower and upper
bounds are provided in Table 2.
Models focussing on cannabis use
Cannabis use was associated with an increased risk of psychotic dis-
orders and of being arrested. The models assumed that cannabis use in
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Table 1
Intervention data.
Study Population Intervention Comparator
Modelled
intervention
effectiveness
Modelled
comparator
effectiveness
Study – Focus on Families Intervention (Catalano
et al., 1999)
Children whose parent
use drugs
Family-based
intervention:
group skills
training for
parents and case
management
Standard
methadone
treatment
Cannabis use was
7% after 12 months
Cannabis use
was 9% after
12 months
A Brief, Web-Based Personalized Feedback
Selective Intervention for College Student
Marijuana Use: A Randomized Clinical Trial (Lee
et al., 2010)
People known to use
drugs occasionally
(subgroup analysis for
people with family
history of drug use
problems)
Web-based
intervention
based on
motivational
interviewing and
skills training
Assessment
only
control
Cannabis use
reduced by 37%
after month 6, 25%
after month 12 and
13% after month
18
No change
from baseline
The efficacy of Familias Unidas on drug and
alcohol outcomes for Hispanic delinquent youth:
Main effects and interaction effects by parental
stress and social support (Prado et al., 2012)
children and young
people who are in
contact with young
offender teams but not
in secure environments
Family-based
intervention:
group skills
training for
parents
Community
Practice
Reduction in drug
use from 27% at
baseline to 16%
and 10% at month
6 and month 12
respectively
Reduction
from 32% to
26% at month
6, and then an
increase to
36% at month
12
Brief intervention for regular ecstasy (MDMA)
users: Pilot randomized trial of a Check-up model
(Martin & Copeland, 2010)
People known to use
drugs occasionally
Single session
motivational and
cognitive
behavioural
intervention
Assessment
only
32.6% reduction in
ecstasy use at three
months
No change
from baseline
A randomized controlled trial utilizing
motivational interviewing to reduce HIV risk and
drug use in young gay and bisexual men (Parsons
et al., 2014)
people who are lesbian,
gay, bisexual or
transgender
Motivational
interviewing
Educational
videos and
structured
discussion
Drug use at
baseline, 3, 6, 9
and 12 months
82.2%, 68.9%
63%, 52.7% and
55.9%
Drug use at
baseline, 3, 6,
9 and 12
months 80%,
71%, 74.5%,
61.4% and
61.1%
Randomized Trial to Reduce Club Drug Use and
HIV Risk Behaviors Among Men Who Have Sex
With Men (Morgenstern et al., 2009)
people who are lesbian,
gay, bisexual or
transgender
Motivational
interviewing
Educational
videos
Days of drug use at
baseline, 3, 6, 9
and 12 months 17,
11, 9, 10, and 6
Days of drug
use at baseline,
3, 6, 9 and 12
months 17, 14,
15, 12 and 11
A family intervention to reduce sexual risk
behaviour, substance use, and delinquency among
newly homeless youth (STRIVE) (Milburn et al.,
2012)
People who are
considered homeless
Group skills
training for
parents and
children
Standard
care
Days of drug use at
baseline, 3, 6, 9
and 12 months
were 2.8, 1.3, 0.7,
0.5, and 0.3
Days of drug
use at baseline,
3, 6, 9 and 12
months 2.7,
1.5, 2, 1.6 and
1.2
creased the rate of psychotic disorders from seven in 1000 to 14 in
1000 (Hall, 2015). Annual psychotic disorder-related costs included ser-
vice costs (£13,136) and informal care costs (£4242). Psychotic dis-
orders were assumed to reduce health related quality of life from 1
to 0.68 (McCrone et al., 2009) (where 1 is equivalent to full health
and 0 is equivalent to being dead). It was estimated that there are
50.27 cannabis possession arrests per 1000 cannabis users based on po-
lice recorded data from 2014 to 15, costing £500 per arrest. The cost
of £500 is based on the average time it takes an officer to deal with
an offence, noting that this cost is low as most cannabis possessions
are assumed not to result in court activity (May, Duffy, Warburton,
& Hough, 2007).The literature indicated that cannabis use may be as-
sociated with an increased risk of road traffic accidents (Gadegbeku,
Amoros, & Laumon, 2011; Hartman & Huestis, 2013) but the advisory
committee which developed the guideline was not convinced of the ro-
bustness of these estimates, and so they were included in sensitivity
analysis only. Cannabis-related lung cancer was excluded from the mod-
els as robust UK data were not identified. Our modelled social costs for
one year of cannabis use are shown in Fig. 1.
Three interventions reported changes in cannabis use: Focus on Fam-
ilies, the web-based personalised feedback intervention, and Familias
Unidas.
Focus on families
Seven percent of children receiving the intervention had used
cannabis 12 months after receiving Focus on Families, compared nine
percent of children in the comparator group (Catalano et al., 1999). The
model did not assume any continued effect beyond the 12 month time
horizon because a follow-up study demonstrated that the intervention
effect was restricted to 12 months (Haggerty, Skinner, Fleming, Gainey,
& Catalano, 2008).
Web-based feedback
The study duration was six months (Lee et al., 2010), and we did
not identify evidence that the duration of effect would be sustained be-
yond the study period. Therefore the base case (most plausible scenario)
considered a one year time horizon, assuming that cannabis use was re-
duced at month six and then rebounded to baseline at month 12. To ex-
plore the sensitivity of the model to this assumption, we considered a
scenario with a two year time horizon, assuming that cannabis use was
reduced at month six, and returned to baseline at 24 months.
Familias unidas
The base case considered the 12 month study duration only. Two
scenarios considered a 24 month time horizon, using the trial data for
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Table 2
Intervention costs.
Drug Study
Intervention
cost
estimate per
client (low,
high)
Cannabis Study – Focus on Families Intervention
(Catalano et al., 1999)
£3367
(£842,
£4209)
A Brief, Web-Based Personalized Feedback
Selective Intervention for College Student
Marijuana Use: A Randomized Clinical Trial
(Lee et al., 2010)
£15 (£1,
£30)
The efficacy of Familias Unidas on drug and
alcohol outcomes for Hispanic delinquent
youth: Main effects and interaction effects by
parental stress and social support (Prado et
al., 2012)
£154 (£116,
£193)
Comparator
£100 (£75,
£125)
Ecstasy Brief intervention for regular ecstasy (MDMA)
users: Pilot randomized trial of a Check-up
model (Martin & Copeland, 2010)
£67 (£32,
£138)
Cocaine A randomized controlled trial utilizing
motivational interviewing to reduce HIV risk
and drug use in young gay and bisexual men
(Parsons et al., 2014)
£268 (£128,
£552)
Randomized Trial to Reduce Club Drug Use
and HIV Risk Behaviors Among Men Who
Have Sex With Men (Morgenstern et al.,
2009)
£268 (£128,
£552)
A family intervention to reduce sexual risk
behaviour, substance use, and delinquency
among newly homeless youth (STRIVE)
(Milburn et al., 2012)
£825 (£619,
£1031)
drug use at baseline, month six, 12 and extrapolating for month 18:
one scenario assumed drug use returned to baseline at month 24, while
the other assumed drug use remained constant beyond the extrapolated
value for month 18.
Models focussing on ecstasy use
Ecstasy use was associated with an increased risk of arrest, hos-
pital admission, accident and emergency attendance, ambulance con-
veyance, death, and drug dependence. The models assumed that each
ecstasy user consumed 40.75 tablets per year, which was calculated
from estimates of the number of tablets consumed per year, UK pop-
ulation data, and the prevalence of ecstasy use (Collins et al., 2016).
The model assumed that there are 0.11 sentences per 1000 ecstasy
users, costing £23,194 per sentence, and 2.13 arrests per 1000 ecstasy
users, costing £1346 per arrest (Advisory Council on the Misuse of
Drugs, 2008; Ministry of Justice, 2014). Rates of hospital admission,
A&E attendance and ambulance conveyance were 2.43, 2.43, and 1.68
per 1000 users, with unit costs of £372, £109 and £216 respectively
(Department of Health, 2014). Ecstasy use also carries a risk of death,
estimated at 0.039 per 1000 users (Office for National Statistics, 2014a,
2014b) which has a cost of £464 to the National Health Service and (dis-
counted) QALY loss of 22.3 for 16–24year olds and 17.9 for 25–59year
olds. The risk of ecstasy dependence is 0.68 per 1000 users with a cost
of £2620 (Collins et al., 2016). Our modelled social costs for one year of
ecstasy use are shown in Fig. 1.
Only the brief motivational intervention studied by Martin and
Copeland (2010) focussed on ecstasy use.
Brief intervention
The study (Martin & Copeland, 2010) reported ecstasy use at base-
line and month three. In the model for the intervention group, we as-
sumed that ecstasy use decreased linearly over the first three months
for the intervention group, and then increased linearly to baseline at
12 months (base case) or 24 months (scenario analysis). The model as-
sumed no change in ecstasy use in the comparator group.
Models focussing on cocaine use
Cocaine use was associated with an increased risk of arrest, hospi-
tal admission, death, and drug dependence. The models assumed that
the risk of cocaine-related arrest was 9.4 per 1000 users at a cost of
£1925 per arrest (Godfrey, Eaton, McDougall, & Culyer, 2002). Hospi-
tal admissions included cocaine-specific diagnoses with a probability of
2.24 per 1000 users and cost per admission of £1765, cocaine-related
cardiovascular admissions with probability 2.20 per 1000 users and
cost per admission of £1678, and cocaine-related myocardial infarctions
with probability of 1.39 per 1000 users and cost per event of £3459
(Godfrey et al., 2002). The probability of being in treatment for depen-
dence on cocaine use varies by age – for people aged 16–19 this was
12.9 per 1000 users and for people aged 30–40 this was 3.44 per 1000
Fig. 1. xxx.
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users. Drug dependence was assumed to lead to a QALY loss of 0.576 per
person (Pyne et al., 2011) and a cost of £1562 for treatment. Cocaine
use carries an annual excess risk of death of 0.048 per 1000 users. The
QALY loss for premature death depends on age and is 20.9 (discounted)
for someone who dies at age 25 and 17.7 (discounted) for someone who
dies at age 39 (Collins et al., 2016). Our modelled social costs for one
year of cocaine use are shown in Fig. 1.
Three interventions reported change in cocaine use: motivational in-
terviewing in young gay and bisexual men, motivational interviewing in
men who have sex with men, and STRIVE.
Motivational interviewing to reduce drug use in young gay and bisexual men
The model assumed that drug use changed between the levels re-
ported in the study (Table 1) until 12 months (the study duration). Be-
tween months 12 and 24, the base case assumed that drug use returned
linearly to baseline, and a scenario analysis extrapolated data from the
first 12 months.
Motivational interviewing to reduce club drug use among men who have sex
with men
The model assumed that the prevalence of drug use changed in line
with the days of drug use from the study (Table 1) until month 12 (the
study duration). Between months 12 and 24, the base case assumed that
drug use returned linearly to baseline, and a scenario analysis extrapo-
lated data from the first 12 months.
STRIVE
The model assumed that prevalence of drug use changed in line with
days of drug use from the study (Table 1), until month 12 (the study
duration). Between months 12 and 24, the base case assumed that drug
use returned linearly to baseline, and a scenario analysis extrapolated
data from the first 12 months.
For all of the models, we performed threshold analyses to explore
the duration of intervention effect needed for each intervention to be
cost-effective.
Results
The base case costs, QALYs and incremental cost-effectiveness ratios
(ICERs) for each intervention are reported in Table 3. ‘Costs’ refers to
both the cost of the intervention (or the comparator) and social costs
associated with drug misuse. ‘QALYs’ refers to the QALY losses as-
sociated with drug misuse only. For all interventions, the base case
ICERs are estimated to be above £100,000/QALY, and well above the
£20,000/QALY level that NICE generally considers for cost-effectiveness
(National Institute for Health & Care Excellence, 2016). This is because
the cost savings and QALY gains from reducing drug use are not large
enough to offset the costs of the interventions.
The QALY losses for each intervention and comparator are small −
in context, a QALY loss of 0.00011 equates to losing one hour of life in
full health. The QALY losses are small because the risk of a person who
misuses a drug experiencing an event which leads to QALY loss is very
low, even though in some cases the QALY loss per event (such as prema-
ture death) can be substantial. Furthermore, three of the interventions
(Catalano et al., 1999; Milburn et al., 2012; Prado et al., 2012) are de-
livered to a population where not all recipients at baseline are misusing
drugs − and so the number of people experiencing a QALY loss is very
small indeed. Therefore, there is limited potential for interventions to
reduce this QALY loss and the resulting incremental QALY gain is very
small.
With low incremental QALYs, ICERs are very sensitive to interven-
tion costs, and so sensitivity analysis for low and high intervention
costs as well as sustained duration of effect is presented in Table 4.
The web-based feedback intervention, which targeted a population who
were all occasional drug users at baseline, becomes dominant (provid-
ing more benefit than comparator at a lower cost) when the cost is re-
duced to £1. At this price, the cost saving from avoiding drug use is
sufficient to offset the intervention cost. It may be feasible for an on-
line intervention to be delivered at such a low cost per person when
provided to a sufficiently large population. Changing the cost of the
Focus on Families intervention does not sufficiently decrease the ICER
for the intervention to be cost-effective. This is because only a small
proportion of the study population uses drugs and the intervention ef-
fect is small. Like Focus on Families, Familias Unidas targets people at
risk of drug use, but has a lower intervention cost and higher incre-
mental effect than Focus on Families. Familias Unidas would be dom-
inant if the duration of effect was sustained and the intervention cost
was £116, but the feasibility of delivering an intensive intervention with
the same effectiveness for such a low cost is unknown. The interven
Table 3
Base case results.
Costs QALYs Incremental Costs Incremental QALYs ICER
Cannabis: Focus on Families
Intervention £1986⁠a −0.000070
Comparator £7 −0.000090 £1979 0.000020 £99,254,920
Intervention
Comparator £21 −0.000176 £8 0.000017 £478,296
Intervention £29 −0.000160
Cannabis: Familias Unidas
Intervention £164 −0.000113
Comparator £123 −0.000281 £40 0.000168 £240,994
Ecstasy: brief intervention
Intervention £75 −0.000689
Comparator £10 −0.000827 £65 0.000139 £471,799
Cocaine: motivational interviewing in young gay and bisexual men
Intervention £339 −0.013035
Comparator £75 −0.0136282 £265 0.000588 £450,471
Cocaine: motivational interviewing among men who have sex with men
Intervention £340 −0.005668
Comparator £88 −0.006943 £252 0.001275 £197,623
Cocaine: STRIVE family intervention among newly homeless youth
Intervention £834 −0.002464
Comparator £12 −0.003313 £822 0.000850 £967,573
ICER: incremental cost-effectiveness ratio, QALYs: quality adjusted life years.
a Assuming 1.7 children per family.
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Table 4
Sensitivity analysis: base case and two year duration with varying intervention costs.
ICER: low
intervention
cost
ICER: mean
intervention
cost
ICER: high
intervention
cost
Cannabis: Focus on
Families
£24,761,038 £99,254,920 £124,096,048
Cannabis: Web-
based feedback(base
case)
Dominant £478,296 £1,011,468
Cannabis: Web-
based feedback(two
year reduction
scenario)
Dominant £213,221 £481,318
Cannabis: Familias
Unidas (base case)
£12,828 £240,994 £472,142
Cannabis: Familias
Unidas (two year
reduction scenario
1)
Dominant £128,162 £278,716
Cannabis: Familias
Unidas (two year
reduction scenario
2)
Dominant £108,644 £245,257
Ecstasy: brief
intervention (base
case)
£219,138 £471,799 £984,340
Ecstasy: brief
intervention (two
year reduction
scenario)
£104,357 £231,477 £489,347
Cocaine:
motivational
interviewing in
young gay and
bisexual men (base
case)
£212,291 £450,471 £933,636
Cocaine:
motivational
interviewing in
young gay and
bisexual men (two
year reduction
scenario)
£66,262 £144,722 £303,884
Cocaine:
motivational
interviewing among
men who have sex
with men (base
case)
£87,784 £197,623 £420,439
Cocaine:
motivational
interviewing among
men who have sex
with men (two year
reduction scenario)
£45,026 £108,098 £236,045
Cocaine: STRIVE
family intervention
among newly
homeless youth
(base case)
£725,080 £967,573 £1,210,066
Cocaine: STRIVE
family intervention
among newly
homeless youth (two
year reduction
scenario)
£504,483 £673,562 £842,642
ICER: incremental cost-effectiveness ratio.
tions for ecstasy and cocaine use are estimated to be not cost-effective
even with a low cost and sustained duration of effect.
The ICERs for Focus on Families and STRIVE remain above £30,000/
QALY even in a scenario where drug use took over 60 years to return
to baseline. The other interventions become cost-effective at £20,000
− £30,000/QALY when the duration of effect increases. For moti-
vational interviewing among men who have sex with men the du
ration of effect needs to be 25–45 years, for motivational interviewing in
young gay and bisexual men and the brief intervention for ecstasy, the
duration needs to be 10–20 years. Familias Unidas and the web-based
feedback are cost-effective with durations of 4–8 years, and actually be-
come cost-saving if the effect is sustained for 11 and 6 years respec-
tively.
Discussion
Although interventions may well exist that are cost-effective in pre-
venting drug misuse in vulnerable populations, these were not included
in the NICE scope and none of the interventions considered in our analy-
ses were estimated to be cost effective in the base case. This is at least
partially due to the relatively low effectiveness of the interventions –
more robust evidence of larger intervention effect sizes would translate
into more favourable cost-effectiveness estimates. However, the analy-
ses were additionally subject to a number of limitations, many of which
are common challenges in the economic evaluation of public health in-
terventions (Weatherly et al., 2009).
Duration of intervention effect
NICE has found interventions to prevent smoking and alcohol mis-
use to be cost-effective (National Institute for Health & Care Excellence,
2010; National Institute for Health & Care Excellence, 2008b; National
Institute for Health & Care Excellence, 2007). However, interventions
with similar costs in drug misuse prevention and alcohol consumption
or smoking have very different cost-effectiveness results. Interventions
that cost £15 per head and prevented smoking prevalence by 0.5% were
estimated to be cost-effective, with ICERs much lower than those for the
web-based intervention included in the current analysis, which also cost
£15 per head (Raikou & McGuire, 2008). Screening to identify people
at increased risk followed by brief advice costing £80 was estimated to
reduce alcohol use by 12.3%, and the ICERs varied between being domi-
nant and £6000/QALY (Purshouse et al., 2009). In comparison, the brief
intervention to reduce ecstasy use had a similar cost and reduced drug
use by 32% but had ICERs above £200,000/QALY.
The effect of the screening followed by brief advice for alcohol con-
sumption was assumed to return to baseline over seven years (Purshouse
et al., 2009), a longer duration than the ecstasy brief intervention model
(12 months). The cost-effectiveness of any intervention is sensitive to
the duration of effect, and Purshouse et al. (2013) found that assuming
that the effect returned to baseline over three years halved the QALY
gain and increased the ICER to £39,000/QALY. We did not identify any
evidence to support conducting analyses with longer duration of effect
for the included interventions and the single study that included longer
term follow up found no effects beyond 12 months (Haggerty et al.,
2008). However, sensitivity analysis demonstrated that with duration of
effect comparable to that of the brief intervention for alcohol, four of
the seven interventions could be cost-effective or even cost-saving.
Long-term consequences of drug misuse
Most interventions to prevent alcohol misuse or smoking are cost-ef-
fective partially because the long term consequences of smoking and
alcohol are well understood and avoidable costs are high (Allender,
Balakrishnan, Scarborough, Webster, & Rayner, 2009; Balakrishnan,
Allender, Scarborough, Webster, & Rayner, 2009; Edkpu & Brown,
2015; Nutt, King, & Phillips, 2010; Scarborough et al., 2011; Wadd &
Papadopoulos, 2014). There is high quality evidence linking alcohol
and smoking to a range of health outcomes such as high blood pres-
sure, heart disease, respiratory disease, cancers, digestive disease and
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road traffic accidents, whereas the evidence for the association be-
tween illicit drug use and these types of outcomes is much weaker. We
note that including cannabis-related road traffic accidents in sensitiv-
ity analyses decreases the ICERs for interventions, for example from
£240,994 to £205,442 for Familias Unidas.
The social costs associated with each drug in our analysis are limited
by the data available, although we note that all were validated through
discussion with a committee of experts. This relative paucity of data is
likely a feature of the comparatively lower drug usage rates in the gen-
eral population: 2.2% of adults are frequent illicit drug users (Home Of-
fice, 2015) compared with 19% of adults who smoke cigarettes (Office
for National Statistics, 2014a) and 79% who drink alcohol (Office for
National Statistics, 2014b). The illicit status of drugs may also lead to
underreporting and further limit the accuracy of estimates. Changes in
drug purity, potency, and the use of substitute and excipient compounds
in some drug preparations also presents additional challenges in under-
standing their long-term consequences (Cole et al., 2011). For example,
there has been a change in the ratio of cannabinoids in analysed sam-
ples of cannabis over the last two decades, which may have implications
for assessments of psychosis risk (Elsohly et al., 2016).
Our models did not consider the ‘gateway theory’ that early adoles-
cent use of cannabis, ecstasy or cocaine can lead to later use of drugs
such as opiates which have much greater social costs. Evidence for gate-
way effects are weak (Degenhardt et al., 2010; Nkansah-Amankra &
Minelli, 2016), but if a causal link does exist then our models would un-
derestimate the benefits and cost-effectiveness of drug misuse preven-
tion programmes. In addition, our models considered illicit drug use in
isolation of alcohol and tobacco use. Unhealthy behaviours often clus-
ter together and have a magnified combined effect, so drug use may
increase the liver damage seen with alcohol use (Degenhardt & Wall,
2012), or cannabis use may increase the lung damage seen with tobacco
use, and may lead to nicotine dependence (Lee & Hancox, 2011).
Appropriateness of the QALY as an outcome
There are harmful effects of drug misuse which our economic mod-
els have not captured. Although we include costs related to crime, drug
misuse may also have (indirect) impact upon attendance and attainment
in education and employment, and an effect on family and social prob-
lems (Lynskey & Hall, 2000; Chatterji 2006; Fergusson, Horwood, &
Beautrais, 2003; Zhang, Brook, Leukefeld, & Brook, 2016). These would
all impact quality of life in a way that health-focussed QALYs do not
capture. We considered the harms and costs associated with the individ-
ual using drugs, but there are also economic, health, and social conse-
quences of involvement in illicit drug market and criminal justice sys-
tem (United Nations Office on Drugs & Crime, 2016). Although presen-
tation of a cost-utility analysis facilitates comparison with interventions
in other health-related areas, and allows NICE to apply decision making
criteria for recommending interventions, this approach may not always
capture the full range of relevant outcomes in a particular domain. This
may be why so few studies were identified in the literature review of
cost-effectiveness evidence.
Perspective of analyses and inclusion of wider outcomes
Our analysis considered only costs to the healthcare and criminal
justice systems and health effects to the individual. Drug misuse may
additionally impact productivity, through difficulty in finding or main-
taining employment, absenteeism and presenteeism, or through prema-
ture death. We considered a scenario in the models focussing on ec-
stasy and cocaine use where premature death was associated with a
loss of earnings, assuming that people would otherwise work until age
65, using mean annual salaries by age band (Office for National
Statistics, 2016). In this scenario, the ICERs decreased to £445,274 for
the brief intervention, £442,324 for motivational interviewing in young
gay and bisexual men, £178,805 for motivational interviewing in men
who have sex with men and £959,695 for STRIVE. These small changes
to the ICER demonstrate that the inclusion of lost productivity due to
death would not change the conclusions of the economic models. This is
because although the cost of lost productivity for one death is relatively
high (£617,966 for a 25-year-old), it is only incurred by a very small
proportion of the population receiving the intervention. Quantifying
and including suffering of family and friends would have increased the
negative outcomes associated with drug misuse for a greater proportion
of the population, but if the per-person impact was relatively low, this
would also have little impact on the ICERs.The interventions included in
our analyses did not all focus solely on reducing drug use. Arguably, in
calculating whether an intervention is cost-effective, we should consider
the potential costs and benefits of its effect on all reported outcomes.
Five studies additionally measured changes in risky sexual behaviour
(Martin & Copeland, 2010; Milburn et al., 2012; Parsons et al., 2014;
Prado et al., 2012). Decreases in risky sexual behaviour may lead to re-
ductions in sexually transmitted infections and unwanted pregnancies.
Incorporating such additional outcomes would be likely to increase the
cost offsets and QALY gains for the interventions and hence decrease the
ICERs, possibly to such a level that the interventions become cost-effec-
tive. Furthermore, the interventions may have reduced use of more than
one drug, which would deliver additional QALY gains and cost offsets
for the same intervention cost, therefore decreasing the ICER. Interven-
tions which additionally reduced use of injectable drugs such as heroin
may lead to reductions in needle-sharing and hence avoid transmission
of disease such as hepatitis, which would have further benefits.
Our study focussed on interventions which targeted high-risk pop-
ulations. There are strong associations between problematic drug use,
socioeconomic disadvantage, co-morbidities, and other vulnerabilities
(e.g. homelessness) (Daniel et al., 2009). It is difficult to disaggregate
the effect of an individual’s drug use from other risk factors in contribut-
ing to harmful outcomes and so primordial prevention of risk factors, as
well as actions to reduce the influence of these risk factors, may impact
upon multiple outcomes (Wilkinson & Pickett, 2010). The models we
developed considered the differential distribution of drug use in study
populations, but there was not sufficient evidence in primary studies to
consider differential outcomes in detail. So, for example, the modelling
took into account the increased likelihood that someone who was home-
less was more likely to use drugs, but not that they might be more likely
to be arrested than a drug user who was not homeless, or that interven-
tion participation also increased the (unmeasured) likelihood that the
individual would find stable housing.
There is little high-quality review-level evidence on the effective-
ness of selective drug prevention programmes (Novakovic et al., 2016)
However, there are multiple levels of influence that might potentially
reduce the propensity to use drugs (Griffin & Botvin, 2010) in higher
risk groups. These include psychobiological, social, family, and socioe-
cological factors, and so programmes designed to improve outcomes in
these domains, although not specified as drug prevention programmes,
may have indirect effects on drug use. For example, the Good Behav-
iour Game is a universal elementary school classroom behaviour man-
agement intervention, and participation has been found to be associ-
ated with lower rates of drug and alcohol use disorders, regular smok-
ing, antisocial personality disorder, criminal justice involvement and
suicide ideation in late adolescence (Kellam et al., 2011). Secondary
analysis suggested that intervention impact might be more pronounced
in those participants rated at higher risk at baseline (Kellam et al.,
2014). Inclusion of data from some universal programmes and includ-
ing a wider range of outcomes in economic evaluation may lead to fur
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ther cost savings and health benefits, and therefore improve the cost-ef-
fectiveness of the intervention.
Targeting interventions
The interventions considered here, as with many public health in-
terventions, are aimed at prevention rather than treatment. This means
that costs are incurred by a whole population, but only a propor-
tion of that population is actually affected as not all would experience
long term drug-related harms. Better targeted interventions at those
sub-populations most at risk of experiencing drug related harms could
increase the proportion of recipients who benefit from the interven-
tions studied, and therefore increase the cost-effectiveness of interven-
tions. However, this requires that the interventions under review have
differential effectiveness for higher risk sub-groups. Whilst analysis of
other prevention programmes has shown this to be the case (Conduct
Problems Prevention Research Group, 2007; Kellam et al., 2008; McKay,
Sumnall, McBride, & Harvey, 2014), others have not (Botvin, Mihalic, &
Grotpeter, 1998; Elliot & Mihalic, 2004; Komro & Toomey, 2002; Spoth,
Shin, Guyll, Redmond, & Azevedo, 2006), and without secondary analy-
sis of the programmes included in the current review, differential effects
cannot be assumed.
Conclusion
Our analysis estimated that none of the seven drug misuse preven-
tion interventions were cost-effective in the base case, because the cost
savings and health benefits from preventing drug use did not sufficiently
offset the intervention costs. Sensitivity analyses demonstrated that
some interventions were cost-effective when a longer duration of inter-
vention effect was assumed, demonstrating the importance of long-term
follow up. Similarly, intervention cost was a key driver of cost-effective-
ness, indicating that consideration should be given to the resources re-
quired to deliver the interventions in specific settings.
The ICERs for some interventions remained high even under more
optimistic assumptions about duration of effect and intervention cost.
This may be because in these cases, the intervention effect size was not
sufficiently large to generate benefits to outweigh the cost. Inclusion of
a broader range of benefits has the potential to reduce the ICERs some-
what, but may not have a substantial impact because only a fraction of
people receiving the intervention are affected by serious consequences.
A greater understanding of the consequences of drug misuse and the
causal factors may facilitate the targeting of interventions to the most
vulnerable populations and lead to more favourable cost-effectiveness
results.
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